alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EX-10.2



 Exhibit 10.2 

CVB FINANCIAL CORP. 2008 EQUITY INCENTIVE PLAN 

AMENDMENT NO. 5 

THIS AMENDMENT NO. 5 (this “Amendment”) to the CVB Financial Corp. 2008 Equity Incentive Plan (the
“Plan”), is adopted by CVB Financial Corp., a California corporation (the “Company”), effective as of March 22, 2017. All capitalized terms in this Amendment shall have the same meaning as in the Plan. 

WHEREAS, pursuant to Section 8.1 of the Plan, the Board of Directors of the Company may, in its sole discretion,
amend the Plan, or any part thereof, at any time and for any reason; provided that no such amendment alters or impairs any rights or obligations under any award previously granted to any participant in the Plan; 

WHEREAS, F.W. Cook prepared an analysis of current director compensation standards for the Compensation Committee of
the Board of Directors supporting 1 year vesting for director restricted stock awards based on continued service; 

WHEREAS, the Board of Directors has deemed it to be in the best interests of the Company to amend Section 6.2 of
the Plan to reduce the minimum period of restriction for restricted stock awards based on continued service and on March 22, 2017, adopted an amendment to the Plan in the form set forth below: 

NOW THEREFORE, in compliance with the terms of the Plan, Section 6.2 of the Plan is amended in its entirety to
read as follows: 
 6.2    Restricted Stock Agreement. Each Award of Restricted Stock shall be
evidenced by an Award Agreement that shall specify the Period of Restriction, the number of Shares granted, and such other terms and conditions as the Administrator, in its discretion, shall determine. The Period of Restriction shall not be less
than one year for Awards that are earned based on the attainment of Performance Goals, not be less than one year for Awards that are earned based on Continuous Status as a Director, and not less than three years for Awards that are earned based on
Continuous Status as an Employee or Consultant. Unless the Administrator determines otherwise, Shares of Restricted Stock shall be held by the Company as escrow agent until the restrictions on such Shares have lapsed. 

Survival. Except as modified hereby, all of the provisions of the Plan remain in full force and effect.








 References. Any reference to the Plan contained in any
document, instrument or agreement executed in connection with the Agreement, shall be deemed to be a reference to the Plan as modified by this Amendment. 

IN WITNESS WHEREOF, this Amendment to the Plan is effective as of the date first above written. 

 

					
	CVB FINANCIAL CORP.
		
	By:	 	/s/ E. Allen Nicholson
		 	Name:	 	 E. Allen Nicholson

		 	Title:	 	 Chief Financial Officer
#### § 801.417 Chlorofluorocarbon propellants.

The use of chlorofluorocarbon in devices as propellants in self-pressurized containers is generally prohibited except as provided in § 2.125 of this chapter.

[43 FR 11318, Mar. 17, 1978]
# C_2016191EN.01003001.xml

| 30.5.2016 | EN | Official Journal of the European Union | C 191/30 |
| --- | --- | --- | --- |

30.5.2016

EN

Official Journal of the European Union

C 191/30

---

Order of the President of the General Court of 7 April 2016 — ADR Center v Commission

(Case T-644/14 R)

((Application for interim measures - Arbitration clause - Agreements concluded for the purpose of carrying out projects subsidised by the European Union within the framework of the ‘Civil Justice’ programme - Enforceable decision of the Commission to recover the sums paid - Application for suspension of operation of a measure - Lack of urgency))

(2016/C 191/39)

Language of the case: English

Parties

Parties

Applicant: ADR Center Srl (Rome, Italy) (represented by: L. Tantalo, lawyer)

Applicant:

Defendant: European Commission (represented by: L. Cappelletti and J. Estrada de Solà, acting as Agents)

Defendant:

Re:

Re:

Application to suspend the enforcement of Commission Decision C(2014) 4485 final of 27 June 2014 concerning the recovery of the sum of EUR 194 275,34, plus interest, owed by ADR Center Srl with reference to debit notes Nos 3241311168, 3241311170 and 3241311175 relating to EUR 62 649,47, EUR 78 991,12 and EUR 52 634,75 respectively.

Operative part of the order

Operative part of the order

| 1. | The application for interim measures is dismissed. |
| --- | --- |

1.

The application for interim measures is dismissed.

| 2. | The order of 22 January 2016 is cancelled in so far as it relates to Case T-644/14 R. |
| --- | --- |

2.

The order of 22 January 2016 is cancelled in so far as it relates to Case T-644/14 R.

| 3. | The costs are reserved. |
| --- | --- |

3.

The costs are reserved.

---
```

[Federal Register Volume 75, Number 7 (Tuesday, January 12, 2010)]
[Notices]
[Page 1608]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-450]

=======================================================================
-----------------------------------------------------------------------

COMMODITY FUTURES TRADING COMMISSION

Sunshine Act Meetings

    The following notice of meeting is published pursuant to the 
provisions of the Government in the Sunshine Act, Public Law 94-409, 5 
U.S.C. 552b.

Agency Holding the Meeting: Commodity Futures Trading Commission.

Time and Date: 1 p.m., January 14, 2010.

Place: Three Lafayette Center, 1155 21st St., NW., Washington, DC, 
Lobby Level Hearing Room (Room 1000).

Status: Open.

Matters to be Considered: Issuance of a proposed rule on energy 
position limits and hedge exemptions on regulated futures exchanges, 
derivatives transaction execution facilities and electronic trading 
facilities.

Contact Person for More Information: David A. Stawick, Secretary of the 
Commission, 202-418-5071.

David A. Stawick,
Secretary of the Commission.
[FR Doc. 2010-450 Filed 1-8-10; 4:15 pm]
BILLING CODE 6351-01-P
```
AFS-12-373-E 

May 31, 2012 

Mr. Richard E. Druschel 

7437 Pine Vista Drive 

Brighton, MI 48116 

Dear Mr. Druschel: 

This letter is in response to your correspondence sent to the public docket dated May 1, 2012 

(public docket No. FAA-2003-16009) petitioning the Federal Aviation Administration for an 

extension to Exemption No. 8125. That exemption from 14 Code of Federal Regulations 

(CFR) § 91.109(a) and (b)(3) allowed you to conduct flight instruction in certain Beechcraft 

aircraft equipped with a functioning throwover wheel instead of functioning dual controls. 

On August 31, 2011, the FAA amended 14 CFR Part 91 related to throwover control wheels 

(76 FR 54095). A copy of this rule change is enclosed for your information. 

Because the relief you seek is now covered under the new rule, we will take no further action 

on your petition. 

Sincerely, 

/s/ 

Ida Klepper 

Manager, Airman and 

Airspace Rules Division
# C_2016156EN.01004202.xml

| 2.5.2016 | EN | Official Journal of the European Union | C 156/42 |
| --- | --- | --- | --- |

2.5.2016

EN

Official Journal of the European Union

C 156/42

---

Order of the General Court of 15 March 2016 — Larymnis Larko v Commission

(Case T-575/14) (1)

1

((Action for annulment - State aid - Privatisation - Support measures for a debtor of the applicant - Decision declaring the aid to be incompatible with the internal market - No interest in bringing proceedings - Inadmissibility))

(2016/C 156/56)

Language of the case: Greek

Parties

Parties

Applicant: Elliniki Metalleftiki kai Metallourgiki Larymnis Larko AE (Kallithea, Greece) (represented by: V. Koulouris, lawyer)

Applicant:

Defendant: European Commission (represented by: A. Bouchagiar, acting as Agent, and by V. Chatzopoulos, lawyer)

Defendant:

Re:

Re:

Application for annulment of Commission Decision 2014/539/EU of 27 March 2014 on the State aid SA.34572 (13/C) (ex 13/NN) implemented by Greece for Larko General Mining & Metallurgical Company SA (OJ 2014 L 254, p. 24).

Operative part of the order

Operative part of the order

| 1. | The action is dismissed as inadmissible. |
| --- | --- |

1.

The action is dismissed as inadmissible.

| 2. | Elliniki Metalleftiki kai Metallourgiki Larymnis Larko AE shall bear its own costs and pay those incurred by the European Commission. |
| --- | --- |

2.

Elliniki Metalleftiki kai Metallourgiki Larymnis Larko AE shall bear its own costs and pay those incurred by the European Commission.

---

(1)  OJ C 395, 10.11.2014.

1

---
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 Current Report

                       Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934

                Date of Report (date of earliest event reported)

                           May 13, 2003 (May 12, 2003)

                     MEDICAL STAFFING NETWORK HOLDINGS, INC.
             (Exact name of registrant as specified in its charter)

           Delaware                     1-31299                 06-0865171
(State or other jurisdiction          (Commission             (IRS Employer
      of incorporation)               File Number)          Identification No.)

                901 Yamato Road, Suite 110, Boca Raton, FL 33431
                    (Address of principal executive offices)

        Registrant's telephone number, including area code: 561-322-1300


<PAGE>

Item 7(c). Exhibits

99.1 Press Release dated May 12, 2003.

Item 9. Regulation FD Disclosure

      The registrant is attaching a copy of a press release dated May 12, 2003
as Exhibit 99.1.

Limitation on Incorporation by Reference

      In accordance with general instruction B.2 of Form 8-K, the information in
this report (including the exhibit) is furnished pursuant to Item 9 and shall
not be deemed to be "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended or otherwise subject to liabilities of that
section. This report will not be deemed an admission as to the materiality of
any information in the report that is required to be disclosed solely by
Regulation FD.


<PAGE>

                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date: May 13, 2003                    MEDICAL STAFFING NETWORK HOLDINGS, INC.

                                      By: /s/ Kevin S. Little
                                          --------------------------
                                          Kevin S. Little
                                          Chief Financial Officer

                                       3

<PAGE>

                                  EXHIBIT INDEX

Exhibit No.    Description

99.1           Press release dated May 12, 2003

                                       4
Exhibit 99(a)


         Written Statement of the President and Chief Executive Officer
                          Pursuant to 18 U.S.C. ss.1350

       Solely for the purposes of complying with 18 U.S.C. ss.1350, I, the
undersigned President and Chief Executive Officer of Ladish Co., Inc. (the
"Company"), hereby certify, based on my knowledge, that the Quarterly Report on
Form 10-Q of the Company for the quarter ended June 30, 2002 (the "Report")
fully complies with the requirements of Section 13(a) of the Securities Exchange
Act of 1934, except that, for the reasons described in the Report, the Company's
independent public accountants have been unable to complete their review of the
unaudited consolidated financial statements included in the Report as required
by Rule 10-01(d) of Regulation S-X; and that information contained in the Report
fairly presents, in all material respects, the financial condition and results
of operations of the Company.




 /s/  Kerry L. Woody
---------------------------------
Kerry L. Woody
August 13, 2002
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.1840 Diagnostic spirometer. ( a ) *Identification.* A diagnostic spirometer is a device used in pulmonary function testing to measure the volume of gas moving in or out of a patient's lungs.
( b ) *Classification.* Class II (performance standards).
****EXHIBIT 32****

CERTIFICATE OF PRINCIPAL EXECUTIVE OFFICER AND 

PRINCIPAL FINANCIAL OFFICER PURSUANT TO 

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of GVC Venture Corp. (the “Company”) on Form 10-Q for the quarter ended March 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bernard Zimmerman, Principal Executive Officer and Principal Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002        that, to the best of my knowledge:

|   | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------|

|   | (2) | The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------|

 

 

| Date: May 8, 2009 | /s/ Bernard Zimmerman                                                              |
|-------------------|-----------------------------------------------------------------------------------------|
|              | Bernard Zimmerman, President                                                            |
|              | (Principal Executive Officer) and Treasurer (Principal Financial andAccounting Officer) |
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1565 6-Phosphogluconate dehydrogenase test system. ( a ) *Identification.* A 6-phosphogluconate dehydrogenase test system is a device intended to measure the activity of the enzyme 6-phosphogluconate dehydrogenase (6 PGD) in serum and erythrocytes. Measurements of 6-phosphogluconate dehydrogenase are used in the diagnosis and treatment of certain liver diseases (such as hepatitis) and anemias.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 53 FR 21449, June 8, 1988; 66 FR 38788, July 25, 2001]
§ 520.2455 Tiamulin. ( a ) *Specifications.* ( 1 ) Each gram of soluble powder contains 450 milligrams (mg) tiamulin hydrogen fumarate.
( 2 ) Each milliliter (mL) of solution contains 125 mg (12.5 percent) tiamulin hydrogen fumarate.
( 3 ) Each mL of solution contains 123 mg (12.3 percent) tiamulin hydrogen fumarate.
( b ) *Sponsors.* See sponsor numbers in § 510.600(c) of this chapter for use as in paragraph (d) of this section. ( 1 ) No. 058198 for products described in paragraph (a) of this section.
( 2 ) No. 066104 for product described in paragraph (a)(1) of this section.
( 3 ) Nos. 016592, 051072, 051311, and 061133 for product described in paragraph (a)(2) of this section.
( 4 ) No. 054771 for product described in paragraph (a)(3) of this section.
( c ) *Related tolerances.* See § 556.732 of this chapter.
( d ) *Conditions of use in swine* — ( 1 ) *Amounts and indications for use.* Administer in drinking water for 5 consecutive days: ( i ) 3.5 mg per (/) lb of body weight daily for treatment of swine dysentery associated with *Brachyspira hyodysenteriae* susceptible to tiamulin.
( ii ) 10.5 mg/lb of body weight daily for treatment of swine pneumonia due to *Actinobacillus pleuropneumoniae* susceptible to tiamulin.
( 2 ) *Limitations.* Use as only source of drinking water. Prepare fresh medicated water daily. Withdraw medication 3 days before slaughter following treatment at 3.5 mg/lb and 7 days before slaughter following treatment at 10.5 mg/lb of body weight. Swine being treated with tiamulin should not have access to feeds containing polyether ionophores (e.g., lasalocid, monensin, narasin, salinomycin, or semduramicin) as adverse reactions may occur. The effects of tiamulin on swine reproductive performance, pregnancy, and lactation have not been determined.
[70 FR 75017, Dec. 19, 2005, as amended at 74 FR 7180, Feb. 13, 2009; 75 FR 54492, Sept. 8, 2010; 77 FR 56770, Sept. 14, 2012; 78 FR 17596, Mar. 22, 2013; 80 FR 13229, Mar. 13, 2015; 85 FR 18119, Apr. 1, 2020; 87 FR 17945, Mar. 29, 2022; 87 FR 58962, Sept. 29, 2022]
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.500 Saffron. ( a ) *Identity.* ( 1 ) The color additive saffron is the dried stigma of Crocus sativus L. The definition of saffron in this paragraph is for the purpose of identity as a color additive only, and shall not be construed as setting forth an official standard for saffron under section 401 of the act.
( 2 ) Color additive mixtures made with saffron may contain as diluents only those substances listed in this subpart as safe and suitable in color additive mixtures for coloring foods.
( b ) *Uses and restrictions.* Saffron may be safely used for the coloring of foods generally, in amounts consistent with good manufacturing practice, except that it may not be used to color foods for which standards of identity have been promulgated under section 401 of the act, unless the use of added color is authorized by such standards.
( c ) *Labeling.* The color additive and any mixtures intended solely or in part for coloring purposes prepared therefrom shall bear, in addition to the other information required by the act, labeling in accordance with the provisions of § 70.25 of this chapter.
( d ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Page 10293]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4672]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Environmental Health Sciences; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Environmental Health 
Sciences, Special Emphasis Panel, Breast Cancer Center Review 
Committee.
    Date: March 11-12, 2010.
    Time: 12 p.m. to 1 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Little America Hotel Salt Lake City, 500 South Main 
Street, Salt Lake City, UT 84101.
    Contact Person: Linda K. Bass, Scientific Review Administrator 
Scientific Review Branch, Division of Extramural Research and 
Training, Nat. Institute Environmental Health Sciences, P. O. Box 
12233, MD EC-30, Research Triangle Park, NC 27709, (919) 541-1307, 
<a href="/cdn-cgi/l/email-protection#0e6c6f7d7d4e60676b667d2060676620696178"><span class="__cf_email__" data-cfemail="5f3d3e2c2c1f31363a372c7131363771383029">[email protected]</span></a>.

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.115, 
Biometry and Risk Estimation--Health Risks from Environmental 
Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety 
Training; 93.143, NIEHS Superfund Hazardous Substances--Basic 
Research and Education; 93.894, Resources and Manpower Development 
in the Environmental Health Sciences; 93.113, Biological Response to 
Environmental Health Hazards; 93.114, Applied Toxicological Research 
and Testing, National Institutes of Health, HHS)

    Dated: February 24, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-4672 Filed 3-4-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
EXHIBIT 32 CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO 
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of GVC Venture Corp. (the "Company") on Form 10-QSB for the quarter ended
March 31, 2006, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Bernard Zimmerman,
Principal Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that, to the best of my knowledge:  (1)
The
                                        Report fully complies with the requirements of
Section 13(a) or 15(d)                                         of the Securities Exchange
Act of 1934; and  (2)
The
information contained in the report fairly presents, in all material respects, the
financial condition and results of operations of the Company.  Date: May 2, 2006
                              /s/ Bernard ZimmermanBernard Zimmerman,
                                        President
       (Principal Executive Officer) and
                                               Treasurer (Principal Financial and
       Accounting Officer)